Diffuse alveolar hemorrhage (DAH) is a poorly understood complication of transplantation carrying a high mortality. Patients commonly deteriorate and require intensive care unit (ICU) admission. Treatment with high-dose steroids and aminocaproic acid (ACA) has been suggested. The current study examined 119 critically ill adult hematopoietic transplant patients treated for DAH. Patients were subdivided into low-, medium-and high-dose steroid groups with or without ACA. All groups had similar baseline characteristics and severity of illness scores. Primary objectives were 30, 60, 100 day, ICU and hospital mortality. Overall mortality (n = 119) on day 100 was high at 85%. In the steroids and ACA cohort (n = 82), there were no significant differences in 30, 60, 100, day, ICU and hospital mortality between the dosing groups. In the steroids only cohort (n = 37), the low-dose steroid group had a lower ICU and hospital mortality (P = 0.02). Adjunctive treatment with ACA did not produce differences in outcomes. In the multivariate analysis, medium-and high-dose steroids were associated with a higher ICU mortality (P = 0.01) as compared with the low-dose group. Our data suggest that treatment strategies may need to be reanalyzed to avoid potentially unnecessary and potentially harmful therapies.
INTRODUCTION
Pulmonary complications occur in up to 60% of hematopoietic SCT (HSCT) recipients and are a leading cause of morbidity and mortality. [1] [2] [3] [4] Diffuse alveolar hemorrhage (DAH) is a syndrome consisting of hypoxia, multilobar pulmonary infiltrates and progressively bloody bronchoalveolar lavage (BAL) fluid. 5 It has been reported to affect~5-12% of HSCT patients yearly; however, more recent studies indicate the incidence to be closer to 5%. [6] [7] [8] BAL fluid, however, lacks sensitivity and specificity when compared with autopsy findings, which hinders early and accurate diagnoses. 9 Despite prompt therapy and supportive care, the mortality rate for DAH remains high at 60-100%. Patients commonly require intensive care unit (ICU) admission and invasive mechanical ventilation; therefore, there is an imminent need to better clarify optimal treatment strategies.
All previous studies to date specifically on DAH have been retrospective in nature. High-dose steroids have historically been suggested as the primary therapy for noninfectious DAH to neutralize the inflammatory insult theorized to be an underlying cause of hemorrhage. 8, [10] [11] [12] [13] [14] [15] Post-HSCT DAH patients have an increased number of bronchial neutrophils and eosinophils on pre-transplant bronchoscopy as compared with their counterparts without DAH. 16 The unwanted side effects, however, such as myopathy, glucose intolerance, psychiatric disturbances and an increased susceptibility of infections mandate the judicious use of steroids. [17] [18] [19] [20] Furthermore, treatment strategies vary widely in many transplant centers 10, 11 and the benefit of high-dose steroids in critically ill DAH patients remains undefined. Adjunctive therapies such as the antifibrinolytic agent aminocaproic acid (ACA) have also been proposed, 15 and over 60% of ICU patients with DAH in our institution receive intravenous ACA despite the uncertain efficacy.
The limitation in available data, persistently poor outcomes and ambiguity surrounding optimal treatment prompted our institution to analyze critically ill post-HSCT patients receiving various therapies for DAH. We describe the characteristics of critically ill patients with alveolar hemorrhage at a large HSCT center, and evaluate the differences in mortality when patients are treated with varying doses of steroids with or without ACA.
MATERIALS AND METHODS
The study was approved by The University of Texas MD Anderson Cancer Center Institutional Review Board before initiation. All consecutive adult patients admitted to the ICU between October 2007 and June 2011 who received intravenous steroid therapy on or after ICU admission were retrospectively screened via manual chart review. HSCT recipients who received steroid therapy ± ACA for DAH treatment were included. Exclusion criteria included age o18, or steroids ± ACA administration for non-DAH illnesses. Patients were initially stratified based on treatment with (A) steroids only or (B) steroids with ACA. Within each group, patients were categorized based on the initial dose of methylprednisolone: (1) low dose: o250 mg/day, (2) medium dose: 250-1000 mg/day and (3) high dose: ⩾ 1000 mg/day. Dosing for the first 5 days of therapy was measured. Steroid dose, tapering strategies and ACA treatment were determined by the oncologists and/or ICU-attending physicians. Diagnostic methods included: (I) classic diagnostic criteria (progressively bloody BAL fluid, 420% hemosiderin-laden macrophages (HLMs) on BAL and/or alveolar hemorrhage on autopsy) 5, 6, 21 or (II) clinical diagnoses based on diffuse pulmonary infiltrates (after exclusion of other entities such as pulmonary edema), hemoptysis (if present), hypoxemia and/or bloody BAL fluid.
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Patients with classic diagnostic criteria were later analyzed separately. Positive respiratory cultures within 7 days pre-or-post the DAH diagnosis date were recorded. Patients with negative respiratory cultures were also later analyzed separately. Date of DAH diagnosis was the date of diagnostic bronchoscopy or first physician documentation of clinical DAH onset (whichever came first).
Data collection
Data collection included the following: (1) patient demographics, (2) basic ICU admission laboratory data, (3) admission severity of illness scores (Acute Physiologic and Chronic Health Evaluation II (APACHE II) 22 and Sequential Organ Failure Assessment (SOFA) 23 scores, (4) transplantrelated characteristics including transplant type, date, source, donor relation, allogeneic type, myeloablative vs nonmyeloablative regimen, and acute GVHD data, (5) days post-transplant (days between HSCT and DAH diagnosis), (6) BAL fluid characteristics and cytology, (7) respiratory culture results and antibiotic treatments, (8) days spent on invasive mechanical ventilation, (9) steroid dosages (first 5 days) and (10) 30-day, 60-day, 100-day ICU and hospital mortality. Survival time was designated as time from DAH diagnosis to time of death. Patients were censored on last follow-up if death did not occur.
Statistical analysis
The primary objective of this analysis was to examine the clinical characteristics of this cohort and describe the 30-day, 60-day, 100-day ICU and hospital mortality for patients on the various doses of steroids. Secondary objectives were to evaluate (1) the mortality rates in patients receiving adjunctive ACA; (2) other parameters such as ventilator days and length of stay; (3) the potential risk factors for 30-day ICU and hospital mortality in patients treated for DAH. Frequencies and percentages were reported for categorical variables (such as treatment, dose level and complications). The mean and s.d. were reported for continuous variables (such as age, platelet count and SOFA score). The χ 2 test or Fisher's exact test was used to evaluate the association between two categorical variables. Wilcoxon's rank sum test was used to compare the distributions of continuous variables among two different patient groups. The KruskalWallis test was used to compare the distributions of continuous variables among three different patient groups. The univariate and multivariate logistic models were used to investigate the effect of patient demographics and basic laboratory data and treatments on mortality (in the ICU, in the hospital and at 30 days). All tests were two-sided. P-values less than 0.05 were considered statistically significant. All analyses were conducted using the SAS (version 9.2, SAS, Cary, NC, USA) statistical software.
RESULTS

Baseline characteristics
During the study period, a total of 2650 adult HSCT's were performed at our institution. A total of 119 critically ill HSCT patients who received methylprednisolone for DAH were identified and included in the analysis. Eighty-two patients concomitantly received ACA for DAH.
Baseline transplant and cancer-related data for all patients are listed in Table 1 . Overall 82% (n = 98) required invasive mechanical ventilation. Baseline data according to steroid dose level are listed for the steroid and ACA cohort (Table 2 ) and the steroid-only cohort (Table 3) . Ninety-eight percent of patients were initiated on steroids at or after ICU admission, and no steroid dose escalations were performed in the 5-day time frame. All patients were on broad antibiotic therapy at the time of DAH diagnosis, and 35% of the patients had positive respiratory cultures. Eighty percent of all patients (n = 95) underwent bronchoscopy; BAL cytology results were unavailable for 10 of the patients; however, in the remaining 89% the mean percentage of HLMs was 51% with 73% of patients having ⩾ 20% HLM.
Overall mortality Mortality rates for the designated subgroups are listed in Tables 4  and 5 . For all 119 patients, the overall mortality was 62%, 78% and 85% at 30, 60 and 100 days, respectively. The overall ICU mortality was 51% and hospital mortality 76%. The mortality at 1 year was 90%, and at last follow-up (mean of 4.7 years) was 94%.
Steroids with ACA A total of 82 patients received low-, medium-or high-dose steroids and ACA (4 g IV bolus, 1-g/h infusion). There was a higher percentage of males (P = 0.004) and lower percentage of acute GVHD in the high-dose steroid group (P = 0.04). All other baseline characteristics were otherwise similar, including baseline severity of illness scores (SOFA and APACHE II). There were no significant differences found in 30 day, 60 day, 100 day, ICU or hospital mortality. In addition, there were no differences in ventilator days, ICU length of stay (LOS) and hospital LOS (Table 4) .
Steroids only
Of the 37 patients who received steroid therapy alone, there was a higher percentage of myeloablative regimens (P = 0.03) and a higher incidence of acute GVHD (P = 0.04) in the low-dose steroid group as compared with the other two groups. There were no other significant differences in baseline characteristics, including baseline severity of illness scores (SOFA and APACHE II). The ICU mortality was lower (22.2%) in the group that received low-dose steroids as compared with the medium-dose (63.6%) and highdose (75%) groups (P = 0.02, Table 4 ). Similarly, there was a lower hospital mortality in the low-dose steroid group (P = 0.02). No significant differences were found in 60-or 100-day mortality, ventilator days, ICU and hospital LOS.
Subset analysis
Patients who met classic diagnostic criteria and noninfectious cases (no positive respiratory cultures within 7 days ± DAH diagnosis date) were separately analyzed based on steroid dosing (± ACA). The significant findings for each subset of patients are listed in Table 5 . The baseline characteristics measured were identical to the aggregate group (see variables listed in Tables 2  and 3 ) and were not different, except for those listed in Table 5 . The results were similar to the aggregate data showing no significant differences in mortality or LOS between the various steroid-dosing groups.
Steroids vs steroids and ACA Outcomes related to treatment with or without ACA were evaluated for all 119 patients. There were higher number of mismatched allogeneic donors in the steroids plus ACA group (40%) vs steroids alone group (14%, P = 0.02). No differences were found, however, in donor relation, severity of illness scores or all other baseline characteristics. Between the steroid alone group (n = 37) and the steroids plus ACA group (n = 82), there were no significant differences found in 30 day, 60 day, 100 day, ICU or hospital mortality. There were also no differences found in ventilator days, ICU LOS and hospital LOS. In the multivariate analysis of all 119 patients, treatment with or without ACA was not significantly associated with mortality after adjusting for other prognostic factors (Table 6 ). The incidence of potential complications of ACA treatment such as deep vein thrombosis/pulmonary embolism, myocardial infarction and ischemic stroke were evaluated for up to 30 days post-DAH diagnosis and no differences were found between either cohort (P40.05).
Multivariate analysis Univariate and multivariate analyses were performed on the entire group of patients (n = 119) for ICU, hospital and 30-day mortality (Table 6 ). In the multivariate logistic regression analysis, age and APACHE II score were significant prognostic factors for 30-day mortality. International normalized ratio was a significant prognostic factor for ICU mortality, and SOFA score was a significant prognostic factor for hospital mortality. Medium-and high-dose steroids were both found to be associated with a higher ICU mortality and medium-dose steroids were associated with a higher hospital mortality (Table 6 ). Treatment with ACA was not significantly associated with any mortality measure after adjusting for other factors.
DISCUSSION
Steroid treatment practices have been historically guided by retrospective studies with limited numbers of cases. As DAH is still a relatively uncommon complication of SCT with diagnostic challenges, amassing large numbers of patients is often prohibitive. Although retrospective data analyses regarding treatment outcomes necessitate cautious interpretation, our study conducted in a large transplant center suggests that the overall Defined as number of days between HSCT and DAH diagnoses.
Steroids and aminocaproic acid for alveolar hemorrhage NK Rathi et al mortality of critically ill patients with DAH remains unacceptably high, and that current treatment practices for DAH patients with impending or actual organ failure(s) may need to be re-evaluated. In DAH patients admitted to our ICU, there were no significant differences in mortality between the groups receiving low-, medium-and high-dose steroids. We also found no differences in outcomes associated with adjunctive ACA treatment. Prospective studies in this ICU population are urgently needed because of their high risk of rapid clinical deterioration and death; however, this may prove to be a daunting task because of diagnostic challenges, including the inability to perform BALs in patients with a high acuity of illness and unstable respiratory status. In addition, previous studies cite a reluctance to participate on the part of patients and caretakers for various reasons. 24 Metcalf et al. 11 first retrospectively reported various doses of steroids and their outcomes in DAH (n = 63), and found an improved survival in patients receiving 430 mg/day of methylprednisolone compared with no steroids. Only 52% in the Metcalf study required intubation at diagnosis, however, with an undefined percentage of ICU patients. Afessa et al.
10 also retrospectively studied 36 DAH patients with varying steroid doses, but conversely found no significant differences in survival between the steroid-dosing groups. In their study, 85% were critically ill, which could explain the similarity in findings.
The unacceptably high mortality of DAH despite steroids and supportive care make adjunctive treatments with the potential to improve outcomes and reduce the need for steroids appealing. DAH, which is categorized as injury primarily originating at the vascular endothelial level, falls under the umbrella of idiopathic pulmonary syndrome. 25 Although it is overall still a poorly understood entity, preclinical animal models suggest that donorderived TNF-α, for example, is a significant contributor to lung injury, inflammation and subsequent endothelial cell apoptosis. [25] [26] [27] Agents such as the TNF-α inhibitor etanercept (for idiopathic pulmonary syndrome) have been studied in conjunction with low-dose steroids; however, inherent difficulties surrounding completion of randomized controlled trials in this cohort of patients resulted in a recent underpowered study with negative results. 24 Other agents such as recombinant factor VIIa have also been studied retrospectively, with a recent study suggesting no benefit. 7 ACA is an antifibrinolytic agent classically used intravenously to control perioperative bleeding, mainly in cardiac surgery. [28] [29] [30] [31] To our knowledge, the only previous study of i.v. adjunctive ACA for DAH was performed by Wanko et al.
15 in 14 patients. They retrospectively described an improved 100-day mortality in eight patients who received ACA combined with highdose steroids, vs six patients who received steroids alone. Although patients with positive respiratory cultures were also included, only 28% of their patients were critically ill and baseline severity of illness scores for intergroup comparison was unavailable. In our institution, 69% of ICU patients during the study period were placed on ACA for DAH. The decision to add ACA is dependent on the typical practices of the inpatient oncologist and/or ICU attending. The exact rationale for initiating treatment was not obtainable. The possibility that sicker patients were more likely to receive adjunctive ACA is lessened by the similarity in baseline severity of illness scores, which were significant prognostic factors for survival in the multivariate analysis. Although prospective randomized studies would ultimately be needed to truly determine if ACA can improve outcomes, the 82 ICU patients 
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in our study who received adjunctive ACA did not have a lower mortality or ICU/hospital LOS. Although there was not an increased incidence of thrombotic complications seen in the ACA group, it should be noted that only those patients who underwent diagnostic studies for thromboembolic disease, stroke or myocardial infarction could be retrospectively evaluated. In actual practice, DAH is often a clinical diagnosis resulting in treatment with steroids and other adjunctive therapies. Diagnosing DAH in HSCT patients can be profoundly challenging, as BAL cytology may produce both false-positive and falsenegative results. Although classic definitions of DAH include the presence of 420% HLM on cytology or progressively bloody BAL fluid, Agusti et al. 9 found that on autopsies of DAH patients within 7 days of bronchoscopy, 50% of patients with DAH on autopsy did not have progressively bloody lavage fluid. Similarly, 54% of patients with progressively bloody lavage fluid did not have evidence of DAH on autopsy. Early BAL may also result in missed diagnoses, as it may take 48-72 h before an alveolar macrophage digests enough iron to stain hemosiderin-positive. 32 We chose to include both patients with clinical diagnoses as well as those meeting classic diagnostic criteria in the primary analysis. Our subset analysis of patients who met classic diagnostic criteria revealed results that were consistent with the aggregate group (Table 5) ; sample sizes were comparable to those in other studies specifically addressing DAH treatment. 7, 10, 12, 13, 15 Similarly, although classic definitions of DAH excluded the presence of infection, 5, 6, 25 patients with positive cultures (infection-associated hemorrhage) are nevertheless frequently treated with high-dose steroids. 1, 2, 7, 8, 15 In patients with progressive respiratory failure despite broad antibiotic therapy, it is often unknown whether isolated pathogens are truly causative of hemorrhage, or whether negative cultures accurately exclude infection. Majhail et al. 8 first described patients with infectionassociated hemorrhage treated with steroids. They reported clinical presentations, treatment responses and outcomes similar to noninfectious DAH, and at 60 days found that high-dose steroids had similar survival rates as compared with no treatment. 8 In a recent retrospective study by Elinoff et al. 7 on factor VIIa for DAH treatment, 65% of patients had infection-associated hemorrhage and 95% of those patient received corticosteroids. In our study, 35% of patients had positive respiratory cultures, but received treatment modalities similar to noninfectious DAH because of clinical deterioration despite broad-spectrum antibiotic administration. 8, 15 After excluding cases of infection-associated hemorrhage in the subset analysis, there were still no differences in mortality between the various steroid groups. The valid concern that high-dose steroids could exacerbate existing infections, however, underscores the importance of determining the optimal dose of steroid treatment.
A limitation of our study is that patients who were perceived to be sicker at the time of DAH diagnosis could have inherently been placed on higher doses of steroids or ACA by their treating physicians. Ideally, prospective studies would ultimately be needed for clarification. Although not perfect, severity of illness scores such as SOFA 23 and APACHE 22 help to objectively measure the true degree of illness in ICU patients and may estimate their predicted risk of death. For example, a patient with active hemoptysis may be perceived to be more acutely ill; however, the actual level of respiratory compromise is more accurately measured by the degree of hypoxemia (SOFA and APACHE components). In our multivariate analysis, APACHE II and SOFA scores were found to be significant prognostic factors for 30-day and hospital mortality, respectively. When comparing baseline data, we found no significant differences in admission SOFA and APACHE II scores between the various groups. Steroid treatment was initiated for the vast majority of patients within 24 h of ICU admission. In addition, the percentages of nonmyeloablative regimens and acute GVHD 6, 33 were not reduced in the low-dose steroid group (Tables 2 and 3 ). There were also no significant differences in the number of days between transplant and DAH diagnosis. It must be noted, however, that there are limitations when using admission severity of illness scores as a predictor of mortality, especially in cancer patients. 34 In addition, given that the current study is retrospective in nature, one must exert caution when interpreting these results, as clinician bias in treating sicker patients with higher doses of steroids or ACA cannot be ruled out. Preferably larger sample sizes and randomized studies would ultimately be needed to understand the risks and benefits of the various treatment options.
In summary, patients in our institution admitted to the ICU for post-HSCT DAH had a 100-day mortality of 85%, with prolonged average hospital stays and a high incidence of respiratory failure needing mechanical ventilation. There were no differences in mortality or LOS found between the three steroid-dosing groups, with or without ACA. Despite an overall improved survival for HSCT patients over the past decade, 35 DAH continues to carry a dismal prognosis despite treatment and supportive care. 6, 10, 36, 37 Patients with DAH needing ICU admission represent a cohort with an especially high risk of clinical deterioration and death. This study raises several important questions that deserve further investigation, including the risks and benefits of high-dose steroids and adjunctive therapies, and whether even lower doses of steroids or no treatment would produce similar outcomes. Although the practicality of performing a randomized controlled trial in this cohort remains uncertain, further prospective studies would ultimately be needed to better understand the underlying pathophysiology of DAH to isolate the most effective treatment options in this life-threatening yet poorly understood disease entity. Abbreviations: ACA = aminocaproic acid; APACHE = Acute Physiologic and Chronic Health Evaluation; CI = confidence interval; ICU = intensive care unit; INR = international normalized ratio; OR = odds ratio; SOFA = Sequential Organ Failure Assessment. --* Not significant in the multivariate analysis.
